(Q46489116)

22 December 2017

title

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development (English)

1 reference

22 December 2017

2

Priscilla Biswas

0 references

Antonella Castagna

object named as

Antonella Castagna

1

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

4

0 references

author name string

Priscilla Biswas

2

1 reference

22 December 2017

Alberto Beretta

3

1 reference

22 December 2017

publication date

1 January 2005

1 reference

22 December 2017

published in

Drugs

1 reference

22 December 2017

volume

65

1 reference

22 December 2017

issue

7

1 reference

22 December 2017

page(s)

879-904

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200565070-00001

exact match

0 references

cites work

A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus

1 reference

12 December 2020

Dextrin sulfate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners.

1 reference

12 December 2020

The CD4 antigen: physiological ligand and HIV receptor

1 reference

12 December 2020

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

1 reference

12 December 2020

Enfuvirtide, a new drug for HIV infection

1 reference

12 December 2020

HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

1 reference

12 December 2020

Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

1 reference

12 December 2020

A new classification for HIV-1

1 reference

12 December 2020

Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells

1 reference

12 December 2020

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis

1 reference

12 December 2020

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

12 December 2020

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

12 December 2020

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations

1 reference

12 December 2020

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

12 December 2020

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection

1 reference

12 December 2020

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

1 reference

12 December 2020

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children

1 reference

12 December 2020

Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum.

1 reference

12 December 2020

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

1 reference

12 December 2020

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

1 reference

12 December 2020

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

1 reference

12 December 2020

Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism

1 reference

12 December 2020

Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes

1 reference

12 December 2020

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

12 December 2020

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

1 reference

12 December 2020

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

1 reference

12 December 2020

New antiretroviral agents in the clinic.

1 reference

12 December 2020

1 reference

12 December 2020

Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1

1 reference

12 December 2020

Resistance to enfuvirtide, the first HIV fusion inhibitor

1 reference

12 December 2020

The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides

1 reference

12 December 2020

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

12 December 2020

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

1 reference

12 December 2020

A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide

1 reference

12 December 2020

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

Expression of the HTLV-III envelope gene by a recombinant vaccinia virus

1 reference

12 December 2020

Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients

1 reference

12 December 2020

Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor

1 reference

12 December 2020

Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20.

1 reference

12 December 2020

The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain

1 reference

12 December 2020

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

1 reference

12 December 2020

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

1 reference

12 December 2020

Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates.

1 reference

12 December 2020

Identification of the residues in human CD4 critical for the binding of HIV.

1 reference

12 December 2020

Membrane-anchored peptide inhibits human immunodeficiency virus entry

1 reference

12 December 2020

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

1 reference

12 December 2020

Atomic structure of a thermostable subdomain of HIV-1 gp41

1 reference

12 December 2020

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

1 reference

12 December 2020

Are fusion inhibitors active against all HIV variants?

1 reference

12 December 2020

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

12 December 2020

HIV-1 gp41 as a target for viral entry inhibition

1 reference

12 December 2020

Discontinuation of the clinical development of fusion inhibitor T-1249.

1 reference

12 December 2020

HIV-infected cells are killed by rCD4-ricin A chain

1 reference

12 December 2020

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

1 reference

12 December 2020

Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4.

1 reference

12 December 2020

The entry of entry inhibitors: a fusion of science and medicine

1 reference

12 December 2020

The introduction of the fusion inhibitors in the HAART-regimens.

1 reference

12 December 2020

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

1 reference

12 December 2020

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

1 reference

12 December 2020

1 reference

12 December 2020

Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane

1 reference

12 December 2020

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

12 December 2020

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

12 December 2020

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

1 reference

12 December 2020

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex

1 reference

12 December 2020

Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

1 reference

12 December 2020

Identification of the fusion peptide of primate immunodeficiency viruses

1 reference

12 December 2020

Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

1 reference

12 December 2020

Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection

1 reference

12 December 2020

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

1 reference

12 December 2020

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment

1 reference

12 December 2020

The CD4-gp120 interaction and AIDS pathogenesis

1 reference

12 December 2020

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

1 reference

12 December 2020

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

12 December 2020

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

12 December 2020

G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4.

1 reference

12 December 2020

Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue

1 reference

12 December 2020

Effects of a soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro.

1 reference

12 December 2020

Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates

1 reference

12 December 2020

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection

1 reference

12 December 2020

Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells

1 reference

12 December 2020

Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1.

1 reference

12 December 2020

A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients

1 reference

12 December 2020

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

1 reference

12 December 2020

Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains

1 reference

12 December 2020

Soluble CD4 enhances simian immunodeficiency virus SIVagm infection

1 reference

12 December 2020

Enfuvirtide: antiretroviral class 4, drug 1.

1 reference

12 December 2020

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

1 reference

12 December 2020

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

1 reference

12 December 2020

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

1 reference

12 December 2020

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen

1 reference

12 December 2020

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

12 December 2020

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

1 reference

12 December 2020

Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41

1 reference

12 December 2020

Immunological and virological study of enfuvirtide-treated HIV-positive patients

1 reference

12 December 2020

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

12 December 2020

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

1 reference

12 December 2020

Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.

1 reference

12 December 2020

Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor

1 reference

12 December 2020

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

1 reference

12 December 2020

Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

1 reference

12 December 2020

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

1 reference

12 December 2020

Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages

1 reference

12 December 2020

Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen

1 reference

12 December 2020

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

12 December 2020

Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity

1 reference

12 December 2020

The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

1 reference

12 December 2020

A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells

1 reference

12 December 2020

Characterization and anti-HIV properties of CD 4-coated red blood cells

1 reference

12 December 2020

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

1 reference

12 December 2020

Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus

1 reference

12 December 2020

Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy

1 reference

12 December 2020

Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events

1 reference

12 December 2020

Chemokine receptors as new molecular targets for antiviral therapy.

1 reference

12 December 2020

Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

1 reference

12 December 2020

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

1 reference

12 December 2020

Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding

1 reference

12 December 2020

Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site

1 reference

12 December 2020

Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk

1 reference

12 December 2020

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

12 December 2020

HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages

1 reference

12 December 2020

The MHC-binding and gp120-binding functions of CD4 are separable

1 reference

12 December 2020

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

12 December 2020

US FDA approves new class of HIV therapeutics

1 reference

12 December 2020

International union of pharmacology. XXII. Nomenclature for chemokine receptors

1 reference

12 December 2020

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

12 December 2020

T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor.

1 reference

12 December 2020

The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor

1 reference

12 December 2020

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure

1 reference

12 December 2020

Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

1 reference

12 December 2020

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

12 December 2020

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

1 reference

12 December 2020

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

12 December 2020

1 reference

12 December 2020

Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor

1 reference

12 December 2020

Chemokine receptors: gateways to inflammation and infection

1 reference

12 December 2020

Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A

1 reference

12 December 2020

Epitopes of the CD4 antigen and HIV infection

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells

1 reference

12 December 2020

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development

1 reference

12 December 2020

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

1 reference

12 December 2020

Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions

1 reference

12 December 2020

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20.

1 reference

12 December 2020

HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication

1 reference

12 December 2020

In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication

1 reference

12 December 2020

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

1 reference

12 December 2020

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

1 reference

12 December 2020

The brightening future of HIV therapeutics

1 reference

12 December 2020

Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism

1 reference

12 December 2020

Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like regio

1 reference

12 December 2020

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120

1 reference

12 December 2020

The chemokine system: redundancy for robust outputs

1 reference

12 December 2020

Large-scale manufacture of peptide therapeutics by chemical synthesis

1 reference

12 December 2020

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

1 reference

12 December 2020

New Antiretroviral Agents for the Treatment of HIV Infection

1 reference

12 December 2020

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

12 December 2020

HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.

1 reference

12 December 2020

10.2165/00003495-200565070-00001

Identifiers

DOI

1 reference

22 December 2017

Dimensions Publication ID

1026278597

0 references

1 reference

22 December 2017